Market Intelligence, Clinical Progress, and High-Purity Reagents for Metastasis, Inflammation, and Diabetic Nephropathy Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HPSE drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HPSE Recombinant Protein (Active & Pro-Enzyme Forms) High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed. GST-tag or His-tag options available. |
View HPSE Products |
| Gene Delivery | HPSE Lentivirus Particles (ORF Expression) Full-length HPSE with native secretion signal for stable cell line construction. |
View HPSE Products |
| Benchmark Ab | Anti-HPSE Neutralizing Antibody (Recombinant) Positive control for competitive binding assays and assay normalization. |
View HPSE Products |
| Validator | HPSE siRNA Set (3 target-specific sequences) For knockdown verification and specificity checks in invasion assays. |
View HPSE Products |
| Related Target A | SDC1 (Syndecan-1 / CD138) Primary substrate for HPSE cleavage; co-target for invasion studies. |
View SDC1 Products |
| Related Target B | MMP9 (Matrix Metalloproteinase-9) Synergistic protease in extracellular matrix remodeling and tumor metastasis. |
View MMP9 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pro-Enzyme vs Active Enzyme Discrimination | Both Latent (Pro-HPSE) and Cleaved (Active) forms available; theoretical MW verified by SEC-HPLC and SDS-PAGE |
| Enzymatic Activity Validation | High-purity (>95%) preparations with confirmed specific activity using heparan sulfate substrate degradation |
| Cross-species Preclinical Translation | Human, Mouse, and Cynomolgus HPSE proteins with >90% sequence homology for species bridging studies |
| Enzyme Stability and Processing | Properly folded, HEK293-expressed active-form constructs with native glycosylation |
| Specificity vs Other Glucuronidases | Endotoxin-controlled (<1 EU/μg) proteins suitable for sensitive cellular assays without LPS interference |
| Lack of Reliable Controls | Sequence-verified benchmark antibodies included for normalization; validated siRNA for knockdown specificity |
Live HPSE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of heparanase (HPSE) represents a critical strategy in blocking tumor metastasis and angiogenesis. As a unique endo-β-D-glucuronidase that cleaves heparan sulfate chains on proteoglycans, HPSE facilitates extracellular matrix (ECM) breakdown, releasing growth factors and promoting cell invasion. The race for HPSE therapeutics is transitioning from broad-spectrum small molecule inhibitors to selective biologics and neutralizing antibodies. As first-generation small molecules face bioavailability and heterogeneity challenges, the next wave of R&D is targeting isoform-specific inhibition, pH-dependent activity modulation, and combination therapies that address tumor microenvironment (TME) resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / Glycomimetics | Progen Pharmaceuticals, RedHill Biopharma, Sigma-Tau | Multiple Myeloma, Solid Tumors (Colorectal, Pancreatic) | Enzymatic screening assays (need active HPSE with native glycosylation) |
| Neutralizing Antibody / Biologics | Emerging Biotech Pipeline | Metastatic Cancers, Solid Tumors | Affinity measurement and epitope mapping (need Pro- vs Active-state proteins) |
| Combination Therapy | Academic/Translational | Refractory Solid Tumors, Diabetic Kidney Disease | Pathway validation (need related targets like SDC1 and MMP9; cellular invasion assays with lentivirus overexpression) |
TarMart provides research-use-only reagents. All products undergo sequence verification and endotoxin testing.